JP5797112B2 - 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 - Google Patents

心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 Download PDF

Info

Publication number
JP5797112B2
JP5797112B2 JP2011518734A JP2011518734A JP5797112B2 JP 5797112 B2 JP5797112 B2 JP 5797112B2 JP 2011518734 A JP2011518734 A JP 2011518734A JP 2011518734 A JP2011518734 A JP 2011518734A JP 5797112 B2 JP5797112 B2 JP 5797112B2
Authority
JP
Japan
Prior art keywords
days
neuregulin
hours
administration
ggf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011518734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528353A (ja
JP2011528353A5 (enExample
Inventor
アンソニー カッジャーノ
アンソニー カッジャーノ
アニンディタ ガングリー
アニンディタ ガングリー
ジェニファー イアチ
ジェニファー イアチ
トム パーリー
トム パーリー
Original Assignee
アコーダ セラピューティクス インコーポレイテッド
アコーダ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アコーダ セラピューティクス インコーポレイテッド, アコーダ セラピューティクス インコーポレイテッド filed Critical アコーダ セラピューティクス インコーポレイテッド
Publication of JP2011528353A publication Critical patent/JP2011528353A/ja
Publication of JP2011528353A5 publication Critical patent/JP2011528353A5/ja
Application granted granted Critical
Publication of JP5797112B2 publication Critical patent/JP5797112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011518734A 2008-07-17 2009-07-17 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 Expired - Fee Related JP5797112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
US61/135,171 2008-07-17
PCT/US2009/004130 WO2010030317A2 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015013248A Division JP6189879B2 (ja) 2008-07-17 2015-01-27 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Publications (3)

Publication Number Publication Date
JP2011528353A JP2011528353A (ja) 2011-11-17
JP2011528353A5 JP2011528353A5 (enExample) 2012-01-05
JP5797112B2 true JP5797112B2 (ja) 2015-10-21

Family

ID=42005671

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011518734A Expired - Fee Related JP5797112B2 (ja) 2008-07-17 2009-07-17 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2015013248A Expired - Fee Related JP6189879B2 (ja) 2008-07-17 2015-01-27 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2017150365A Pending JP2017200949A (ja) 2008-07-17 2017-08-03 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2019124501A Pending JP2019196370A (ja) 2008-07-17 2019-07-03 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2021179961A Pending JP2022023208A (ja) 2008-07-17 2021-11-04 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015013248A Expired - Fee Related JP6189879B2 (ja) 2008-07-17 2015-01-27 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2017150365A Pending JP2017200949A (ja) 2008-07-17 2017-08-03 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2019124501A Pending JP2019196370A (ja) 2008-07-17 2019-07-03 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2021179961A Pending JP2022023208A (ja) 2008-07-17 2021-11-04 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP3338791B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN104623633A (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK2320933T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL3338791T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015129137A (ja) * 2008-07-17 2015-07-16 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2016516016A (ja) * 2013-03-06 2016-06-02 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013149163A1 (en) * 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3353546A1 (en) 2015-09-25 2018-08-01 Douglas B. Sawyer Methods for treating cardiac injury
US11426447B2 (en) * 2016-04-19 2022-08-30 Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli) Neuregulin for the treatment of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
WO2001034174A2 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2005525317A (ja) 2002-01-18 2005-08-25 カイロン コーポレイション Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070010518A1 (en) * 2005-02-18 2007-01-11 Matti Kivikko Method for administering levosimendan
MX2007010603A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013149163A1 (en) 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015129137A (ja) * 2008-07-17 2015-07-16 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
US9956266B2 (en) 2008-07-17 2018-05-01 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
US11235031B2 (en) 2008-07-17 2022-02-01 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
JP2016516016A (ja) * 2013-03-06 2016-06-02 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法

Also Published As

Publication number Publication date
EP3338791B1 (en) 2019-09-18
RU2536938C2 (ru) 2014-12-27
AU2017203528A1 (en) 2017-06-15
CN107019794B (zh) 2021-03-12
ES2763184T3 (es) 2020-05-27
US20110166068A1 (en) 2011-07-07
US20200009228A1 (en) 2020-01-09
JP2011528353A (ja) 2011-11-17
EP2320933A1 (en) 2011-05-18
WO2010030317A2 (en) 2010-03-18
JP6189879B2 (ja) 2017-08-30
JP2015129137A (ja) 2015-07-16
US20160113999A1 (en) 2016-04-28
CA2731113A1 (en) 2010-03-18
CN102159236A (zh) 2011-08-17
PL3338791T3 (pl) 2020-04-30
JP2019196370A (ja) 2019-11-14
AU2009292216B2 (en) 2015-03-05
AU2009292216A1 (en) 2010-03-18
RU2020111236A3 (enExample) 2021-09-21
CN107019794A (zh) 2017-08-08
DK2320933T3 (en) 2018-04-16
RU2719199C1 (ru) 2020-04-17
PL2320933T3 (pl) 2018-07-31
EP2320933A4 (en) 2013-02-27
BRPI0916442A2 (pt) 2018-06-19
AU2015202877A1 (en) 2015-06-18
RU2020111236A (ru) 2021-09-21
RU2011105821A (ru) 2012-08-27
EP3632459A1 (en) 2020-04-08
US9198951B2 (en) 2015-12-01
JP2022023208A (ja) 2022-02-07
US11235031B2 (en) 2022-02-01
ES2664394T3 (es) 2018-04-19
EP2320933B1 (en) 2017-12-27
EP3338791A1 (en) 2018-06-27
US20130324466A1 (en) 2013-12-05
US20180280477A1 (en) 2018-10-04
MX384378B (es) 2025-03-14
RU2698090C2 (ru) 2019-08-22
RU2014141514A (ru) 2016-05-10
MX2011000696A (es) 2011-07-29
AU2015202877B2 (en) 2017-03-09
JP2017200949A (ja) 2017-11-09
HK1256637A1 (en) 2019-09-27
US9956266B2 (en) 2018-05-01
CN104623633A (zh) 2015-05-20
DK3338791T3 (da) 2019-12-16

Similar Documents

Publication Publication Date Title
JP6189879B2 (ja) 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
AU2020204070B2 (en) Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
HK40015761A (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1256637B (en) Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
HK1241715B (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1157181B (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
HK1157181A (en) Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150206

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150403

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150818

R150 Certificate of patent or registration of utility model

Ref document number: 5797112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees